Skip to content

Large Sample, Multicenter, Randomized Controlled Study on the Clinical Efficacy of Moxibustion Combined with Medicine in the Treatment of Chronic Obstructive Pulmonary Disease in Stable Stage

Large Sample, Multicenter, Randomized Controlled Study on the Clinical Efficacy of Moxibustion Combined with Medicine in the Treatment of Chronic Obstructive Pulmonary Disease in Stable Stage

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300069780
Enrollment
Unknown
Registered
2023-03-24
Start date
2023-03-29
Completion date
Unknown
Last updated
2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COPD

Interventions

Intervention group:Heat Sensitive Moxibustion+Buyuan Decoction
control group:Triple inhaler

Sponsors

Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 85 Years

Inclusion criteria

Inclusion criteria: ? Those who meet the GOLD 2023 diagnostic criteria for COPD and have a GOLD grade of 2 or 3; ? Conforming to the characteristics of qi yang deficiency syndrome; ? The patient's symptoms such as cough, expectoration, and dyspnea are stable or mild, lasting for at least 2 weeks; ? Acupoint heat sensitivity occurs in the area between the two lateral lines of Feishu and Geshu points or in the first and second costal spaces of the anterior chest from the inside out to within 6 inches of the bladder meridian of foot Taiyang; ? 40 years = age = 85 years; ? The patient is in a normal state of mind, can correctly express the sense of moxibustion, and acts cooperatively; ? Volunteer and sign an informed consent form.

Exclusion criteria

Exclusion criteria: ? Patients in acute exacerbation stage; ? Patients with other diseases that can cause asthma or dyspnea, such as bronchiectasis, bronchial asthma, cor pulmonale, pulmonary fibrosis, tuberculosis, etc; ? "Patients with severe primary diseases such as cardiovascular, liver, kidney, and hematopoietic systems, mental disorders, and serious diseases that affect their quality of life;"; ? Subjects with skin defects or ulcers at the explored site that are not suitable for mild moxibustion; ? Pregnant or lactating women; ? Those who cannot tolerate moxibustion; ? Hormone dependent patients, or those who have used systemic corticosteroid injections (intravenous, intramuscular, subcutaneous, and oral) within 4 weeks prior to enrollment.

Design outcomes

Primary

MeasureTime frame
Number of acute aggravating events;CAT score;

Secondary

MeasureTime frame
pulmonary function;Six minute walk distance;TCM syndrome integral;

Countries

China

Contacts

Public ContactLan Zhihui

Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine

1574018568@qq.com13970989231

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026